HRP20110853T1 - Pirfenidonska terapija i induktori citokroma p450 - Google Patents
Pirfenidonska terapija i induktori citokroma p450 Download PDFInfo
- Publication number
- HRP20110853T1 HRP20110853T1 HR20110853T HRP20110853T HRP20110853T1 HR P20110853 T1 HRP20110853 T1 HR P20110853T1 HR 20110853 T HR20110853 T HR 20110853T HR P20110853 T HRP20110853 T HR P20110853T HR P20110853 T1 HRP20110853 T1 HR P20110853T1
- Authority
- HR
- Croatia
- Prior art keywords
- pirfenidone
- disease
- patient
- use according
- syndrome
- Prior art date
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title claims abstract 25
- 229960003073 pirfenidone Drugs 0.000 title claims abstract 25
- 239000000411 inducer Substances 0.000 title claims abstract 9
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 claims abstract 8
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims abstract 8
- 230000000391 smoking effect Effects 0.000 claims abstract 7
- 238000011260 co-administration Methods 0.000 claims abstract 6
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract 4
- 229960001225 rifampicin Drugs 0.000 claims abstract 4
- 235000019504 cigarettes Nutrition 0.000 claims abstract 3
- 239000000779 smoke Substances 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 230000036407 pain Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000001375 Facial Neuralgia Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000003389 potentiating effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000004429 Bacillary Dysentery Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 241000219198 Brassica Species 0.000 claims 1
- 235000003351 Brassica cretica Nutrition 0.000 claims 1
- 235000003343 Brassica rupestris Nutrition 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 claims 1
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 102000003820 Lipoxygenases Human genes 0.000 claims 1
- 108090000128 Lipoxygenases Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000012287 Prolapse Diseases 0.000 claims 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 206010040550 Shigella infections Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000004760 Tenosynovitis Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000031737 Tissue Adhesions Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 201000003866 lung sarcoma Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 235000010460 mustard Nutrition 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000005113 shigellosis Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
Pirfenidon za upotrebu u liječenju pacijenta kojem je potrebna pirfenidonska terapija, naznačen time, što liječenje obuhvaća izbjegavanje ili prekid istovremene upotrebe ili zajedničkog davanja jakog induktora citokroma P450 1A2 (CAP1A2) da se izbjegne smanjena izloženost pirfenidonu, pri čemu je jak induktor dim cigareta, pušenje ili rifampicin. Patent sadrži još 12 patentnih zahtjeva.
Claims (13)
1. Pirfenidon za upotrebu u liječenju pacijenta kojem je potrebna pirfenidonska terapija, naznačen time, što liječenje obuhvaća izbjegavanje ili prekid istovremene upotrebe ili zajedničkog davanja jakog induktora citokroma P450 1A2 (CAP1A2) da se izbjegne smanjena izloženost pirfenidonu, pri čemu je jak induktor dim cigareta, pušenje ili rifampicin.
2. Upotreba pirfenidona u proizvodnji lijeka za liječenje pacijenta kojem je potrebna pirfenidonska terapija, naznačena time, što liječenje obuhvaća izbjegavanje ili prekid istovremene upotrebe ili zajedničkog davanja jakog induktora citokroma P450 1A2 (CYP1A2) da bi se izbjegla smanjena izloženost pirfenidonu, pri čemu je jak induktor dim cigareta, pušenje ili rifampicin.
3. Pirfendion za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 2, naznačen time, što liječenje obuhvaća izbjegavanje istovremene upotrebe ili zajedničkog davanja jakog induktora citokroma P450 1A2 (CYP1A2).
4. Pirfenidon za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 2, naznačen time, što pacijent izbjegava istovremenu upotrebu ili zajedničko davanje jakog induktora citokroma P450 1A2 (CYP1A2).
5. Pirfendion za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 2, naznačen time, što je pacijent pušač koji je prekinuo pušenje da bi se izbjegla smanjena izloženost pirfenidonu.
6. Pirfenidon za upotrebu ili upotreba prema zahtjevu 5, naznačen time, što je pacijent prekinuo pušenje u toku 4 tjedna prije davanja pirfenidona.
7. Pirfenidon za upotrebu ili upotreba prema zahtjevu 5, naznačen time, što je pacijent prekinuo pušenje istovremeno sa početkom uzimanja pirfenidona.
8. Pirfenidon za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 2, naznačen time, što je pacijent pušač i izbjegava pušenje kada koristi pirfenidon.
9. Pirfenidon za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 2, naznačen time, što liječenje obuhvaća prekid uzimanja ili izbjegavanje istovremene upotrebe ili zajedničkog davanja rifampicina.
10. Pirfenidon za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 9, naznačen time, što pacijent pati od bolesti izabrane od plućne fibroze, idiopatske pulmonarne fibroze, idiopatske interstinalne pneumonije, autoimune bolesti pluća, benigne hipertrofije prostate, koronarnog ili miokardialnog infarkta, atrijalne fibrilacije, cerebralnog infarkta, miokardialne fibroze, muskuloskeletalne fibroze, post-kirurške adhezije, ciroze jetre, renalne fibrozne bolesti, fibrozne vaskularne bolesti, skleroderme, Hermansky-Pudlakovog sindroma, neurofibromatoze, Alzheimerove bolesti, dijabetičarske retinopatije i /ili lezije na koži, fibrozih limfoidnih čvorova u vezi sa HIV-om, kronične opstruktivne bolesti pluća (COPD), inflamatorne plućne fibroze, reumatoidnog artritisa, reumatoidnog spondilitisa; osteoartritisa; gihta, drugih artritičnih stanja; sepse; septičkog šoka; endotoksičnog šoka; gram negativne sepse; sindroma toksičnog šoka; sindroma miofacialne boli (MPS); šigeloze; astme; respiratornog distres sindroma odraslih; inflamatorne bolesti crijeva; Chronove bolesti; psorijaze; ekcema; ulceroznog kolitisa; glomerularnog nefritisa; skleroderme; kroničnog tiroditisa; Graveove bolesti; Ormondove bolesti; autoimunog gastritisa; miastenije gravis; autoimune hemolitičke anemije; autoimune neutropenije; trombocitopenije; fibroze pankreasa; kroničnog aktivnog hepatitisa koji uključuje fibrozu jetre; akutnu i kroničnu bolest bubrega; fibrozu bubrega; dijabetičarsku nefropatiju; sindrom iritiranih crijeva; gorušicu; restenoze; cerebralnu malariju; moždani udar i ishemične povrede; neuralnu traumu; Alzheimerovu bolest; Huntingtonovu bolest; Parkinsonovu bolest; akutnu i kroničnu bol; alergije; uključujući alergijski rinitis i alergijski konjuktivitis; srčanu hipertrofiju; kronični zastoj srca; akutni koronarni sindrom; kaheksiju; malariju; leprozu; lajšmanijazu; Lajmsku bolest; Reiterov sindrom; akutni sinovitis; mišićnu degeneraciju, burzitis; tenodonitis; tenosinovitis; sindrom hernije, rupture ili prolapsa intervertebralnog diska; osteoporozu; trombozu; silikozu; plućnu sarkozu; bolest resorpcije kostiju, kao što je osteoporoza ili poremećaj kostiju u vezi sa multiplim mijelomom; rak, uključujući ali bez ograničenja na metastaze karcinoma grudi, kolorektalnog karcinoma, malignog melanoma, raka želuca, raka ne-malih stanica pluća; reakciju neprihvaćanja grafta; i autoimune bolesti kao što su multipla skleroza, lupus i fibromijalgija; AIDS i druge virusne bolesti kao što je Herpes Zoster, Herpes Simplex I ili II, virus gripa, ozbiljni akutni respiratorni sindrom (SARS) i citomegalovirus; ili dijabetes melitus, proliferativne poremećaje (uključujući i benigne i maligne hiperplazije), uključujući akutnu mijelogenoznu leukemiju, kroničnu mijelogenoznu leukemiju, Kapošijev sarkom, metastatički melanom, višestruki mijelom, rak dojke, uključujući metastatički rak dojke; kolorektalni karcinom; maligni melanom; rak želuca ; rak ne-malih stanica pluća (NSCLC); metastaze kostiju i slično; poremećaji bola uključujući neuromuskularnu bol; glavobolju, bol uslijed raka; bol zuba, i bol uslijed artritisa; poremećaje angiogeneze uključujući angiogenezu čvrstog tumora, okularnu neovaskularizaciju i hemangiom kod djece; stanja u vezi sa signalizacijom puteva ciklooksigeneze ili lipoksigeneze, uključujući stanja u vezi sa prostaglandin endoperoksi sintetazom-2 (uključujući edem, groznicu, analgeziju i bol); hipoksiju organa; agregacija pločica izazvana trombinom; protozaoalne bolesti.
11. Pirfenidon za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 10, naznačen time, što pacijent ima idiopatsku pulmonarnu fibrozu.
12. Pirfenidon za upotrebu ili upotreba prema zahtjevu 1 do 11, naznačen time, što je pirfenidon davan u ukupnoj dnevnoj dozi od 2400 mg ili 2403 mg po danu.
13. Pirfenidon za upotrebu ili upotreba prema bilo kojem od zahtjeva 1 do 12, naznačen time, što je svaka davana doza pirfenidona 801 mg.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26675309P | 2009-12-04 | 2009-12-04 | |
| US12/684,543 US8084475B2 (en) | 2009-12-04 | 2010-01-08 | Pirfenidone therapy and inducers of cytochrome P450 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110853T1 true HRP20110853T1 (hr) | 2011-12-31 |
Family
ID=42077364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110853T HRP20110853T1 (hr) | 2009-12-04 | 2011-11-16 | Pirfenidonska terapija i induktori citokroma p450 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8084475B2 (hr) |
| EP (3) | EP2308491B1 (hr) |
| JP (3) | JP5753094B2 (hr) |
| KR (2) | KR20110091816A (hr) |
| AT (1) | ATE523197T1 (hr) |
| AU (1) | AU2010212488B2 (hr) |
| CA (1) | CA2710014C (hr) |
| CY (1) | CY1112075T1 (hr) |
| DK (1) | DK2308491T3 (hr) |
| EA (1) | EA026869B1 (hr) |
| ES (1) | ES2395159T3 (hr) |
| GE (1) | GEP20166426B (hr) |
| HK (1) | HK1151725A1 (hr) |
| HR (1) | HRP20110853T1 (hr) |
| IL (1) | IL219056A (hr) |
| MX (1) | MX2012004528A (hr) |
| NZ (1) | NZ599246A (hr) |
| PE (1) | PE20121348A1 (hr) |
| PL (1) | PL2308491T3 (hr) |
| PT (1) | PT2308491E (hr) |
| RS (1) | RS51976B (hr) |
| SG (1) | SG181128A1 (hr) |
| SI (1) | SI2308491T1 (hr) |
| SM (1) | SMT201200003B (hr) |
| TW (2) | TW201315718A (hr) |
| WO (1) | WO2011069089A1 (hr) |
| ZA (1) | ZA201202553B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US8084475B2 (en) * | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| DK2670242T3 (da) | 2011-01-31 | 2022-05-02 | Avalyn Pharma Inc | Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN104812338B (zh) | 2012-11-16 | 2017-09-29 | 茵秋创新有限责任公司 | 斜向膨胀式融合器设备和方法 |
| US10039650B2 (en) | 2013-03-15 | 2018-08-07 | In Queue Innovations, Llc | Expandable fusion cage system |
| US9682071B2 (en) | 2013-03-15 | 2017-06-20 | Intermune, Inc. | Methods of improving microvascular integrity |
| EP3091976A4 (en) | 2014-01-10 | 2017-10-11 | Genoa Pharmaceuticals Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| CN111991393A (zh) * | 2019-09-26 | 2020-11-27 | 深圳先进技术研究院 | 吡非尼酮在制备防治类风湿性关节炎的药物中的应用 |
| WO2021057599A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳先进技术研究院 | 吡非尼酮在制备防治类风湿性关节炎的药物中的应用 |
| CA3160410A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| CA3206840A1 (en) * | 2020-12-31 | 2022-07-07 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5330562A (en) * | 1993-03-12 | 1994-07-19 | Medx, Inc. | Fluidized bed scrubber for use in gas cleaning system |
| US20060110358A1 (en) | 2002-08-28 | 2006-05-25 | Hsu Henry H | Combination therapy for treatment of fibrotic disorders |
| JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Ｋｄｌ株式会社 | ピリドン誘導体の溶液状医薬組成物 |
| US20070072181A1 (en) | 2003-02-28 | 2007-03-29 | Blatt Lawrence M | Combination therapy for treating alphavirus infection and liver fibrosis |
| JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
| US20070092488A1 (en) | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
| US20070053877A1 (en) | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005040758A2 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| CN1846699A (zh) | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
| EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| EP1951233B1 (en) | 2005-10-31 | 2012-03-28 | Intermune, Inc. | Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf) |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US7767700B2 (en) | 2006-12-18 | 2010-08-03 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
| US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| US8084475B2 (en) * | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
-
2010
- 2010-01-08 US US12/684,543 patent/US8084475B2/en active Active
- 2010-03-03 RS RS20110506A patent/RS51976B/en unknown
- 2010-03-03 ES ES10250378T patent/ES2395159T3/es active Active
- 2010-03-03 EP EP10250378A patent/EP2308491B1/en active Active
- 2010-03-03 DK DK10250378.6T patent/DK2308491T3/da active
- 2010-03-03 PL PL10250378T patent/PL2308491T3/pl unknown
- 2010-03-03 AT AT10250378T patent/ATE523197T1/de active
- 2010-03-03 PT PT10250378T patent/PT2308491E/pt unknown
- 2010-03-03 SI SI201030011T patent/SI2308491T1/sl unknown
- 2010-03-03 EP EP11005708A patent/EP2377537A1/en not_active Withdrawn
- 2010-08-17 CA CA2710014A patent/CA2710014C/en active Active
- 2010-08-23 AU AU2010212488A patent/AU2010212488B2/en not_active Revoked
- 2010-12-03 EA EA201200574A patent/EA026869B1/ru not_active IP Right Cessation
- 2010-12-03 PE PE2012000449A patent/PE20121348A1/es not_active Application Discontinuation
- 2010-12-03 KR KR1020117016135A patent/KR20110091816A/ko not_active Application Discontinuation
- 2010-12-03 WO PCT/US2010/058936 patent/WO2011069089A1/en active Application Filing
- 2010-12-03 EP EP20100835205 patent/EP2506849A4/en not_active Withdrawn
- 2010-12-03 NZ NZ599246A patent/NZ599246A/en unknown
- 2010-12-03 US US13/513,472 patent/US8754109B2/en active Active
- 2010-12-03 GE GEAP201012737A patent/GEP20166426B/en unknown
- 2010-12-03 JP JP2011544702A patent/JP5753094B2/ja active Active
- 2010-12-03 KR KR1020127018340A patent/KR101762465B1/ko active IP Right Grant
- 2010-12-03 TW TW101148844A patent/TW201315718A/zh unknown
- 2010-12-03 SG SG2012039624A patent/SG181128A1/en unknown
- 2010-12-03 TW TW099142294A patent/TWI440459B/zh not_active IP Right Cessation
- 2010-12-03 MX MX2012004528A patent/MX2012004528A/es active IP Right Grant
-
2011
- 2011-06-09 HK HK11105854.1A patent/HK1151725A1/xx unknown
- 2011-11-16 HR HR20110853T patent/HRP20110853T1/hr unknown
- 2011-11-22 CY CY20111101128T patent/CY1112075T1/el unknown
- 2011-12-15 US US13/326,971 patent/US8648098B2/en active Active
-
2012
- 2012-01-24 SM SM201200003T patent/SMT201200003B/it unknown
- 2012-04-04 IL IL219056A patent/IL219056A/en active IP Right Review Request
- 2012-04-10 ZA ZA2012/02553A patent/ZA201202553B/en unknown
- 2012-05-22 JP JP2012116700A patent/JP2012153734A/ja active Pending
-
2014
- 2014-05-19 JP JP2014103119A patent/JP2014144980A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110853T1 (hr) | Pirfenidonska terapija i induktori citokroma p450 | |
| HRP20110959T1 (hr) | Pirfenidonska terapija kojom se izbjegava upotreba fluvoksamina | |
| JP2019163290A5 (hr) | ||
| JP2017505808A5 (hr) | ||
| JP2017504650A5 (hr) | ||
| US20090215833A1 (en) | Thermodynamically stable form of a tosylate salt | |
| JP2016523973A5 (hr) | ||
| CA2968633C (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| JP2020528889A5 (hr) | ||
| CN105555786A (zh) | 作为BET蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3,4-b]吡嗪酮 | |
| JP2019519598A5 (hr) | ||
| JP2002526501A5 (hr) | ||
| JP2021507900A5 (hr) | ||
| CA2640672A1 (en) | 3 -deazapurine derivatives as tlr7 modulators | |
| WO2003066604A2 (en) | Novel aryl- and heteroarylpiperazines | |
| ES2365073T3 (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparación y su aplicación en terapéutica. | |
| JP2012507566A5 (hr) | ||
| CA2479126A1 (en) | Combination treatments for chemokine-mediated diseases | |
| JP2019514903A5 (hr) | ||
| JP2011500623A5 (hr) | ||
| WO2006019962B1 (en) | Compositions and methods for treatment of colitis | |
| SI3001903T1 (en) | 1H-pyrazolo (3,4-b) pyridines and their therapeutic uses | |
| JP2008528466A5 (hr) | ||
| JP2007537272A5 (hr) |